Successful treatment with intravenous immunoglobulin (IVIg) in a patient with an acquired factor V inhibitor after liver transplantation

Hugo Guglielmone; Gustavo Jarchum; Salvador Minoldo

doi:10.1160/TH11-05-0307

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 106(05): 985-986
DOI: 10.1160/TH11-05-0307

Letters to the Editor

Schattauer GmbH

Successful treatment with intravenous immunoglobulin (IVIg) in a patient with an acquired factor V inhibitor after liver transplantation

Hugo Guglielmone

¹Servicio de Hematología, Sanatorio Allende, FUNDONHEM (Fundación en Oncohematología) Córdoba, Argentina

²Departamento de Bioquímica Clínica, CIBICI-CONICET, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina

,

Gustavo Jarchum

¹Servicio de Hematología, Sanatorio Allende, FUNDONHEM (Fundación en Oncohematología) Córdoba, Argentina

,

Salvador Minoldo

¹Servicio de Hematología, Sanatorio Allende, FUNDONHEM (Fundación en Oncohematología) Córdoba, Argentina

› Institutsangaben

Abstract

als PDF herunterladen

PDF (71 kb)

Referenzen

References
1 Kane WH, Factor V. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th edn. Philadelphia; J.B. Lippincott Company: 2006: 177-192.
2 Ang AL, Kuperan P, Ng CH. et al. Acquired factor V inhibitor: A problem-based systematic review. Thromb Haemost 2009; 101: 852-859.
3 Milojkovic D, Patel R, Ford E. et al. Acquired factor V inhibitor after haematopoietic stem cell transplantation. Thromb Haemost 2007; 98: 685-687.
4 Bobba RK, Garg P, Arya M. et al. Postoperative bleeding in an elderly patient from acquired factor V inhibitor: rapid response to immunosuppressive therapy. Am J Med Sci 2011; 341: 253-256.
5 Shanmugam H, Jayaranee S, Eow GI. A case report of an acquired inhibitor to coagulation factor V. Haemophilia 2011; 17: 168-170.
6 Lo CY, Jones C, Glader B. et al. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin. Pediatr Blood Cancer 2010; 55: 1195-1197.
7 World Federation of Hemophilia. A laboratory manual. Quantitative measurement of factor VIII inhibitors. Diagnosis if hemophilia and other bleeding disorders, 2nd edn. Published by the World Federation of Hemophilia (WFH) 2010: 108-110.
8 Ajzner E, Balogh I, Haramura G. et al. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 2002; 1: 943-949.
9 Maughan EO, Wilson J, Wilde JT. Spontaneous resolution of acquired factor V inhibitors associated with ovarian carcinoma. Int J Lab Hematol 2007; 29: 316-319.
10 Lian EC, Tzakis AG, Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 2004; 77: 363-365.
11 Leroy-Matheron C, Mallat A, Duvoux C. et al. Inhibitor against coagulation factor V after liver transplantation. Transplantation 1999; 68: 1054-1056.
12 Smith JD, Sindhi R, Rogers R. et al. Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Ann Clin Lab Sci 1998; 28: 280-282.
13 Gordon B, Haire W, Duggan M. et al. Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 1991; 88: 156-159.